HOME >> MEDICINE >> NEWS
Researchers study multi-purpose drug

Researchers at the University of Rochester Medical Center today announced that they have launched a study to determine whether an experimental drug, rimonabant, can slow atherosclerosis, the fatty build-up in arteries that creates heart attack risk. In recent studies, rimonabant has been shown to decrease body weight, improve abnormal levels of blood sugars and fats (cholesterol) and to help willing patients quit smoking. Now researchers hope to add coronary artery disease (CAD), atherosclerosis within the arteries of the heart, to the list of maladies addressed. A decision on whether rimonabant is safe and effective and if so, for which uses, is expected from the U.S. Food and Drug Administration in 2006.

Unlike previous cholesterol drugs that treat some aspect of blood or blood vessel walls, rimonabant is a cannabinoid receptor antagonist, which exerts its effect in parts of the brain that control appetite and addictive behaviors. Results of previous studies show that rimonabant reduces triglycerides and increases HDL-C, or "good" cholesterol, independent of weight loss. The new study, titled STADIVARIUS (Strategy to Reduce Atherosclerosis Development Involving Administration of Rimonabant- The Intravascular Ultrasound Study), will explore whether these effects will impact the progression of atherosclerosis.

"Obesity, diabetes, high cholesterol and coronary artery disease have all reached epidemic proportions to become leading causes of death despite being largely preventable," said Frederick S. Ling, M.D., director of the Cardiac Catheterization Laboratory, associate professor of Medicine at the medical center and principal investigator for STRADIVARIUS. "These risk factors, called metabolic syndrome when combined in one person, feed off each other and are made much worse by smoking. New approaches are urgently needed, and our lab has the tools to measure accurately whether new treatments actually slow the progression of coronary artery diseas
'"/>

Contact: Greg Williams
Greg_Williams@urmc.rochester.edu
University of Rochester Medical Center
1-Feb-2006


Page: 1 2

Related medicine news :

1. Researchers suggest TB screening for all international adoptees
2. Researchers find vitamin B1 deficiency key to vascular problems for diabetic patients
3. Researchers link metal ions to neurodegenerative disease
4. Researchers develop criteria to detect bone mass deficiencies in children with chronic diseases
5. Researchers call for investigation into links between khat use and psychiatric disorders
6. Researchers use MRI to predict recovery after spinal cord injury
7. Researchers find deadly prescription drug effects 6 years before FDA
8. Researchers investigate impact of lifestyle on GI health
9. Researchers begin randomized double-blind trial of airway bypass treatment for emphysema
10. Researchers discover how antibiotic inhibits bacterial growth
11. Researchers urge caution in using ESAs for cancer-related anemia

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Researchers study multi purpose drug

(Date:7/30/2014)... Neil Haley, the Total Tutor host of ... to find out about what is branding, how am I ... , Reynolds is an original founding member of the company ... and CEO of Simply G Media. He has written a ... holds the distinction of completing the Dale Brown and Project ...
(Date:7/30/2014)... Pain Free Living web: Superior Magnetics ... relief and improved performance. This new magnetic sports bracelet ... silicone core that is sheathed in nylon soaked in ... with scalar energy and Schumann frequency thus making it ... 12 years experience developing magnetic bracelets. We developed the ...
(Date:7/29/2014)... Paul Mata, CEO of ‘Create Indestructible Wealth,’ ... 30 Days” E-book. The e-book includes a myriad of fast ... cash. Examples include downloading and utilizing specific phone apps ... people monetize the assets they didn't know they had like ... find in their garage. , After reading the e-book, ...
(Date:7/29/2014)... 1Heart Caregiver Services’ advocacy on ... on Brain Fitness Education brings great acceptance from ... Program Director Tee Barr delivered an exceptional Brain ... and the Assisted Living section of Aegis Ventura ... Christy Rozsa and Aegis Life Neighborhood Director Christine ...
(Date:7/29/2014)... July 29, 2014 Daily Gossip indicates ... as all other disturbing symptoms that hemorrhoids commonly causes. ... researcher and natural medicine expert. , The author ... to the elimination of symptoms such as itching, burning, ... Learn more about the H Miracle by visiting the ...
Breaking Medicine News(10 mins):Health News:Entrepreneur and Vi Millioniare GJ Reynolds Discusses How to Improve Your Brand on the Simply G Radio Show, a Division of the Simply G Media Network 2Health News:Superior Magnetics Released New Magnetic Sports Bracelet for Pain 2Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 4Health News:H Miracle Review Exposes Natural Method to Cure Hemorrhoids 2
(Date:7/30/2014)... YORK , July 30, 2014 ACCESS ... for oncology supportive care, announced that its novel product ... in an article on OncLive.com titled, "Study Finds Mouth ... Cancers."  Dr. Steve Sonis , a leading expert ... seen in the oncology community for evidence-based strategies for ...
(Date:7/30/2014)... ANTONIO , July 30, 2014   ... company focused on innovating lifesaving devices and methods ... $4.5 million in Series A financing, which was ... Proceeds from the deal will allow Bluegrass Vascular ... Access Catheter System, enhance manufacturing capabilities, and proceed ...
(Date:7/29/2014)... Israel , July 30, 2014  Immune ... Stockholm : "IMNP."; "Immune" or "the ... of patients for a Phase II proof of concept ... in the treatment of moderate to severe bullous pemphigoid. ... receive two bertilimumab infusions, at a dose of 10 ...
Breaking Medicine Technology:Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 2Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 3Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 4Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin 5
Cached News: